U.S. Markets close in 1 hr 45 mins

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.305-0.18 (-3.19%)
As of 2:15PM EDT. Market open.
People also watch
Interactive chart
Previous Close5.480
Bid5.280 x 500
Ask5.290 x 800
Day's Range5.260 - 5.640
52 Week Range2.600 - 9.250
Avg. Volume1,827,535
Market Cap426.64M
PE Ratio (TTM)-8.45
EPS (TTM)-0.63
Earnings DateAug 2, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.38
Trade prices are not sourced from all markets
  • Reuters4 days ago

    Shire's swelling disorder drug moves closer to U.S. approval

    Successful late-stage data on Shire Plc's , long-acting preventative treatment for hereditary angioedema (HAE) brings the Dublin-based drugmaker one step closer to U.S. approval, it said on Thursday. The drug, lanadelumab, which is expected to generate more than $2 billion in peak sales will help Shire protect and grow its existing HAE franchise, which accounts for about 10 percent of its profit, analysts said. In Shire's late-stage study, three dosing arms of lanadelumab (150 or 300 mg every four weeks or 300 mg every two weeks) were tested against a placebo in 125 patients.

  • Zacks6 days ago

    Implied Volatility Surging for BioCryst (BCRX) Stock Options

    Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.

  • Thomson Reuters StreetEvents11 days ago

    Edited Transcript of BCRX earnings conference call or presentation 4-May-17 3:00pm GMT

    Q1 2017 BioCryst Pharmaceuticals Inc Earnings Call